JCOGの基本情報 > 研究実績 > 大腸がんグループ

JCOGの基本情報大腸がんグループ

更新日:2015年9月30日

  1. 論文
    1. 委員会承認の治療研究
      JCOG0205
      Y Shimada, T Hamaguchi, J Mizusawa, et al.: Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205. European Journal of Cancer. 50(13): 2231-2240, 2014.
      JCOG0212
      S Fujita, T Akasu, J Mizusawa, et al.: Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 13(6): 616-621, 2012.
      JCOG0404
      S Yamamoto, M Inomata, H Katayama, et al.: Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group study JCOG 0404. Ann Surg. 260(1): 23-30, 2014.
      S Kitano, M Inomata, A Sato, et al.: Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan clinical oncology group study JCOG 0404. Jpn J Clin Oncol. 35(8): 475-477, 2005.
      JCOG0603
      Y Kanemitsu, T Kato, Y Shimizu, et al.: Colorectal Cancer Study Group (CCSG) of Japan Clinical Oncology Group. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol. 39(6): 406-409, 2009.
      JCOG0903
      A Takashima, Y Shimada, T Hamaguchi, et al.: A Phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical Stage II/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC). Jpn J Clin Oncol. 41(5): 713-717, 2011.
      JCOG1006
      Y Takii, Y Shimada, Y Moriya, et al.: A Randmized Controlled Trial of the Conventional Technique Versus the No-touch Isolation Technique for Primary Tumor Resection in Patients with Colorectal Cancer: Japan Clinical Oncology Group Study JCOG1006. Jpn J Clin Oncol. 44(1): 97-100, 2014.
      JCOG1107
      M Inomata, T Akagi, H Katayama, et al.: A randomized controlled trial comparing laparoscopic surgery with open surgery in palliative resection of primary tumor in incurable Stage IV colorectal cancer: Japan Clinical Oncology Group Study JCOG 1107 (ENCORE trial). Jpn J Clin Oncol. 44(11): 1123-1126, 2014.
      JCOG1310
      M Ohue, T Hamaguchi, Y Ito, et al.: A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. Int J Clin Oncol. 20(2): 338-344, 2015.
      S Iwasa, H Souda, K Yamazaki, et al.: Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage III lower rectal cancer. Anticancer Res. 35(3): 1815-1819, 2015.
    2. グループ代表者管理の治療研究
      JCOG0212
      S Fujita, S Yamamoto, T Akasu, et al.: Prognostic Factors of Rectal Cancer Patients with Lateral Pelvic Lymph Node Metastasis. Hepato-Gastroenterology. 59: 2494-2497, 2012.
      S Fujita, S Yamamoto, Y Moriya, et al.: Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Colorectal Dis. 24(9): 1085-1090, 2009
      M Kusters, CJ van de Velde, S Fujita, et al.: Patterns of Local Recurrence in Rectal Cancer: A Single-Center Experience. Ann Surg Oncol. 16(2): 289-296, 2009.
      S Fujita, S Yamamoto, T Akasu, et al.: Prognostic Factors of Rectal Cancer Patients with Lateral Pelvic Lymph Node Metastasis. Hepato-Gastroenterology. 59: 2494-2497, 2012.
      JCOG0404
      T Etoh, M Inomata, M Watanabe, et al.: Success rate of informed consent and factors influencing participation in a multicenter randomized controlled trial of laparoscopic versus open surgery for stage II/III colon cancer in Japan (JCOG0404). Asian J Endosc Surg. Epub ahead of print, 2015.
      K Nakajima, M Inomata, T Akagi, et al.: Quality control by photo documentation for evaluation of laparoscopic and open colectomy with D3 resection for stage II/III colorectal cancer: Japan Clinical Oncology Group study JCOG 0404. Jpn J Clin Oncol. 44(9): 799-806, 2014.
      S Kitano, M Kitajima, F Konishi, et al.: A multicenter study on laparoscopic surgery for colorectal cancer in Japan. Surg Endosc. 20(9): 1348-1352, 2006.
      JCOG0603
      K Kato, Y Inaba, Y Tsuji, et al.: A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. Jpn J Clin Oncol. 41(1): 63-68, 2011.
      T Kato, K Yasui, Y Kanemitsu, et al.: Staging and indications for hepatectomy in hepatic metastases of colorectal cancer. Nihon Geka Gakkai zasshi. 107(3): 104-108, 2006.
      T Kato, K Yasui, T Hirai, et al.: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis for prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 46 Suppl: S22-S31, 2003
      JCOG0903
      A Takashima, Y Shimada, T Hamaguchi, et al.: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol. 14(5): 416-420, 2009.
    3. 附随研究等
      JCOG0205/0910
      T Watanabe, M Itabashi, Y Shimada, et al.: Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 20(2): 207-39, 2015.
      Y Takatsuno, K Mimori, K Yamamoto, et al.: The rs6983267 SNP is associated with MYC transcription efficiency, Which promotes progression and worsens prognosis of colorectal cancer. Ann Surg Oncol. 20(4): 1395-1402, 2013.
      T Watanabe, M Itabashi, Y Shimada, et al.: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 17(1): 1-29, 2012.
      Y Hashiguchi, K Hase, H Ueno, et al.: Impact of race/ethnicity on prognosis in patients who underwent surgery for colon cancer: analysis for white, African, and East Asian Americans. Ann Surg Oncol. 19(5): 1517-1528, 2012.
      K Kotake, S Honjo, K Sugihara, et al.: Number of lymph nodes retrieved is an important determinant of survival of patients with stage II and stage III colorectal cancer. Jpn J Clin Oncol. 42(1): 29-35, 2012.
      Y Takahashi, K Mimori, K Yamamoto, et al.: Genomic copy number of a carcinogenic single nucleotide polymorphism at 8q24 in non-risk allele colorectal cancer associated with insulin growth factor 2 receptor expression. J Gastroenterol Hepatol. 27 Suppl 3: 95-99, 2012.
      S Ishimaru, K Mimori, K Yamamoto, et al.: Increased risk for CRC in diabetic patients with the nonrisk allele of SNPs at 8q24. Ann Surg Oncol. 19(9): 2853-2858, 2012
      Y Yoneyama, M Ito, M Sugitou, et al.: Postoperative lymphocyte percentage influences the long-term disease-free survival following a resection for colorectal carcinoma. Jpn J Clin Oncol. 41(3): 343-347, 2011.
      Y Hashiguchi, K Hase, H Ueno, et al.: Optimal margins and lymphadenectomy in colonic cancer surgery. Br J Surg. 98(8): 1171-1178, 2011.
      H Ueno, H Mochizuki, K Shirouzu, et al.: Actual status of distribution and prognostic impact of extramural discontinuous cancer spread in colorectal cancer. J Clin Oncol. 29(18): 2550-2556, 2011
      Y Hashiguchi, K Hase, H Ueno, et al.: Prognostic significance of the number of lymph nodes examined in colon cancer surgery: clinical application beyond simple measurement. Ann Surg. 251(5): 872-881, 2010.
      Y Yamada, T Arao, K Matsumoto, et al.: Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. Cancer Sci. 101(8): 1886-1890, 2010.
      JCOG0212
      Y Akagi, K Shirouzu, S Fujita, et al.: Predicting oncologic outcomes by stratifying mesorectal extension in patients with pT3 rectal cancer: a Japanese multi-institutional study. Int J Cancer. 131(5): 1220-1227, 2012.
      K Shirouzu, Y Akagi, S Fujita, et al.: Clinical significance of the mesorectal extension of rectal cancer: a Japanese multi-institutional study. Ann Surg. 253(4): 704-710, 2011.
      Y Nishizawa, M Ito, N Saito, et al.: Male sexual dysfunction after rectal cancer surgery. Int J Colorectal Dis. 26(12): 1541-1548, 2011.
      KY Tan, S Yamamoto, S Fujita, et al.: Improving prediction of lateral node spread in low rectal cancers-multivariate analysis of clinicopathological factors in 1,046 cases. Langenbecks Arch Surg. 395(5): 545-549, 2010.
      H Kobayashi, H Mochizuki, T Kato, et al.: Is total mesorectal excision always necessary for T1-T2 lowe rectal cancer?. Ann Surg Oncol. 17(4): 973-980, 2010.
      S Noura, M Ohue, Y Seki, et al.: Feasibility of a Lateral Region Sentinel Node Biopsy of Lower Rectal Cancer Guided by Indocyanine Green Using a Near-Infrared Camera System. Ann Surg Oncol. 17(1): 144-151, 2009.
      S Noura, M Ohue, Y Seki, et al.: Evaluation of the lateral sentinel node by indocyanine green for rectal cancer based on micrometastasis determined by reverse transcriptase-polymerase chain reaction. Oncol Rep. 20(4): 745-750, 2008.
      JCOG0603
      Y Shimizu, K Yasui, T Sano, et al.: Validity of observation interval for synchronous hepatic metastases of colorectal cancer: changes in hepatic and extrahepatic metastatic foci. Langenbecks Arch Surg 393(2): 181-184, 2008.
      Y Kanemitsu, T Kato: Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. World J Surg. 32(6): 1097-1107, 2008.
      Y Shimizu, K Yasui, T Sano, et al.: Treatment strategy for synchronous metastases of colorectal cancer is hepatic resection after an observation interval appropriate?. Langenbecks Arch Surg. 392(5): 535-538, 2007.
      安井健三、清水泰博、平井孝、他:【大腸癌治療の進歩】大腸癌肝転移の外科治療-多施設における根治的肝切除例の検討.癌と化学療法.31(5):690-694,2004.
      安井健三、清水泰博、平井孝、他:【転移性肝癌 どこまでchallengeすべきか】大腸癌肝転移の生物学的特性-大腸癌肝転移の腫瘍辺縁形態と予後.外科.66(13):1610-1614,2004.
      JCOG1007
      K Shitara, K Matsuo, C Kondo, et al.: Prolonged Survival of Patients with Metastatic Colorectal Cancer following First-Line Oxaliplatin-Based Chemotherapy with Molecular Targeting Agents and Curative Surgery. Oncology. 81(3-4): 167-174, 2011.
      JCOG1018
      長島文夫、濱口哲弥、古瀬純司:JCOG高齢者研究小委員会の活動と高齢大腸癌を対象とした臨床研究について.癌と化学療. 42(1): 16-20, 2015.
      長島文夫、濱口哲弥:高齢者大腸癌の臨床的問題と化学療法の実際. 消化器の臨床. 17(4): 350-355, 2014.
      JCOG1107
      T Akagi, M Inomata, S Kitano, et al.: Multicenter study of short- and long-term outcomes of laparoscopic palliative resection for incurable, symptomatic stage IV colorectal cancer in Japan. J Gastrointest Surg. 17(4): 776-783, 2013.
    4. 総説・解説
      JCOG0205/0910
      Y Shimada, et al.: Postoperatie adjuvant chemotherapy for colon cancer. Oxaliplatin combination does not help better treatment outcome. Gan To Kagaku Ryoho. 39(11): 1646-1649, 2012.
      森谷宜皓、島田安博、濱口哲弥、他:【いま必要な外科治療に関する臨床試験の最新知識】[領域別]外科治療の臨床試験の問題点と今後の展望 大腸癌の外科治療に関するわが国の臨床試験.臨床外科.66(5):610-616,2011.
      石黒めぐみ、石川敏昭、植竹宏之、他:【医療経済からみた大腸癌化学療法】大腸癌術後補助化学療法の医療経済性評価.臨床外科.66(1):46-52,2011.
      植竹宏之、石川敏昭、杉原健一:【大腸癌 最新の研究動向】大腸癌の治療戦略 化学療法 Stage II・III大腸癌に対する術後補助化学療法.日本臨床.69(増刊3 大腸癌):418-421,2011.
      植竹宏之、石川敏昭、杉原健一:【消化器癌化学療法2011-最近の話題】大腸癌の術後補助化学療法 推奨レジメンをどう使い分けるか?.臨床消化器内科.26(6):661-666,2011.
      濱口哲弥:【最新の大腸癌補助化学療法】大腸がんの術後補助療法(Stage III)国内外臨床試験成績と標準治療.大腸癌FRONTIER.3(1):20-23,2010.
      島田安博、濱口哲弥:【大腸癌治療ガイドラインのエビデンスと解説】高齢者に対する術後補助療法「高齢者における5-FU-based chemotherapy有用性」「カペシタビン療法」「オキサリプラチン併用療法」.ガイドラインサポートハンドブック 大腸癌.杉原健一 編.医薬ジャーナル社.129-132,2010.
      島田安博、濱口哲弥:【大腸癌治療ガイドラインのエビデンスと解説】術後補助化学療法「5-FU/LVからFOLFOXまで」「分子標的治療薬を用いた補助療法」.ガイドラインサポートハンドブック 大腸癌.杉原健一 編.医薬ジャーナル社.112-119,2010.
      JCOG0212
      森谷冝皓、赤須孝之、藤田伸、他:下部直腸癌側方リンパ節転移の治療-JCOG0212からJCOGXXへ.日本外科学会雑誌.112(5):325-329,2011.
      藤田伸、山本聖一郎、赤須孝之、他:進行下部直腸癌の治療成績と補助放射線治療の必要性.癌の臨床.55(2):101-105,2009.
      藤田伸:【直腸癌治療の新知見】JCOG0212(臨床病期II・IIIの下部直腸がんに対する側方リンパ節郭清術の意義に関するランダム化比較試験).大腸癌Frontier.2(3):217-220,2009.
      JCOG0404
      猪股雅史、他:進行結腸癌に対する腹腔鏡下手術-厚生労働省班研究に基づく本邦の現況-.日本内視鏡外科学会雑誌.13(1):47-53,2009.
      M Inomata, K Yasuda, S Kitano, et al.: Clinical evidences of laparoscopic versus open surgery for colorectal cancer. Jpn J Clin Oncol. 38(8): 471-477, 2009.
      JCOG0603
      加藤知行、金光幸秀、小森康司:大腸癌肝転移の治療戦略-大腸癌肝転移治療の変遷.消化器外科.35(9):1355-1366,2012.
      清水泰博、安井健三、佐野力、他:大腸癌同時性肝転移の治療成績 待機肝切除は妥当か?.消化器内科.50(1):80-85,2010.
      加藤知行、安井久晃、島田安博、他:【最新の大腸癌補助化学療法】大腸癌肝転移切除成績の現状-切除可能肝転移に対する術後補助化学療法.大腸癌Frontier.3(1):40-46,2010.
      金光幸秀、加藤知行、小森康司、他:【大腸癌肝転移に対する治療のUpdate】大腸癌取扱い規約(第7版)で一新した肝転移分類(H分類とGrade分類).外科治療.102(6):821-828,2010.
      金光幸秀:肝転移補助化学療法後の補助化学療法.ガイドラインサポートハンドブック 大腸癌.杉原健一 編?.医薬ジャーナル社.123-127,2009.
      平井孝、加藤知行、金光幸秀:【大腸癌治療ガイドラインをめぐって】大腸癌血行性転移の治療 肝・肺転移.大腸癌Frontier.1(1):34-38,2008.
      加藤知行、平井孝、清水康博、他:【Stage IV大腸癌と診断したらどうするか】肝転移を伴うStage IV大腸癌の治療方針.外科治療.96(6):984-991,2007.
      加藤知行、平井孝、金光幸秀、他:【大腸疾患の外科 最新の諸問題】大腸癌肝転移・肺転移に対する治療方針 最近の諸問.外科.68(9):1058-1066,2006.
      平井孝、加藤知行、金光幸秀:大腸癌肝転移に関する研究-大腸癌の肝転移に対する外科治療.大腸疾患NOW.89-104,2004.
      JCOG0903
      高梨以美、斉藤聖宏、江口真理子、他:肛門扁平上皮癌に対する同時化学放射線療法例の検討.臨床放射線.55(9):1121-1128,2010.
      赤木由人、白水和雄、衣笠哲史、他:肛門扁平上皮癌.別冊 日本臨牀 新領域症候群シリーズ.12:746-748,2009.
      JCOG1006
      平井孝、金光幸秀、小森康司:手術手技 結腸右半切除D3郭清 no touch isolationと支配動脈走行variationへの対応.手術.64(7):1169-1175,2010.
      JCOG1007
      金光幸秀:切除不能な遠隔転移例における原発巣切除.ガイドラインサポートハンドブック 大腸癌.杉原健一 編.?医薬ジャーナル社.82-85,2009.
      JCOG1018
      長島文夫、北村浩、高須充子、他:がん診療における総合的機能評価.腫瘍内科.9(6):734-742,2012.
      濱口哲弥:高齢者大腸がんに対する薬物療法.腫瘍内科.8(3):222-229,2011.
  2. 主な学会発表
    1. 委員会承認の治療研究
      JCOG0205
      金光幸秀、島田安博、中村健一、他:臨床病期III期大腸癌に対する術後補助化学療法の第III相試験(JCOG0205).第50回日本癌治療学会学術集会.2012年10月.
      植竹宏之、石川敏昭、石黒めぐみ、他:わが国における大腸癌術後補助化学療法の大規模比較臨床試験-JCOG0205 MF-.第37回日本外科系連合学会学術集会.2012年6月.
      Y Shimada, T Hamaguchi, Y Moriya, et al.: Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III colon cancer (CC): Final results of Japan clinical oncology group study (JCOG0205). 48th Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol 30 (suppl; abstr 3524) , Jun 2012.
      Y Shimada, T Hamaguchi, Y Moriya, et al.: Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III colon cancer (CC): Final results of Japan Clinical Oncology Group study (JCOG0205). 48th Annual Meeting of the American Society of Clinical Oncology. Jun 2012.
      濱口哲弥、島田安博、斎藤典男、他:JCOG0205 Stage III治癒切除大腸がんに対する術後補助療法のランダム化第III相比較臨床試験)UFT/LVの補助療法としての臨床評価.第44回日本癌治療学会総会.2006年10月.
      島田安博、濱口哲弥、森谷冝皓、他:JCOG0205 Stage III治癒切除大腸がんに対する術後補助療法のランダム化第Ⅲ相比較臨床試験:5FU/l-LV対UFT/LV.第60回日本大腸肛門病学会総会.2005年10月.
      JCOG0212
      S Fujita, S Saito, Y Moriya, et al.: Morbidity and mortality Results from a Prospective Randomized Trial Comparing Mesorectal Excision (ME) and ME with Lateral Lymph Node Dissection for Stage II, III Lower Rectal Cancer. Japan Clinical Oncology Group Study 0212 (NCT00190541). 47th Annual Meeting of the American Society of Clinical Oncology. Jun 2011.
      JCOG0404
      S Fujii, M Inomata, T Akagi, et al.: Transitional impact of short and long-term outcomes of a randomized controlled trial to evaluate laparoscopic versus open surgery for colorectal cancer from Japan Clinical Oncology Group Study JCOG0404. European Cancer Congress. Sep 2015.
      T Hanai, J Okuda, T Yatsuoka, et al.: Institutional heterogeneity of survival and morbidity in laparoscopic surgery for colorectal cancer: From the data of a randomized controlled trial comparing open and laparoscopic surgery (JCOG0404). European Cancer Congress. Sep 2015.
      T Akagi, M Inomata, H Katayama, et al.: A randomized controlled trial to evaluate laparoscopic versus open with Japanese D3 dissection for stage II,III colorectal cancer (CRC): First efficacy results from Japan Clinical Oncology Group Study JCOG0404. ASCO 2015. May 2015.
      M Inomata, H Katayama, J Mizusawa, st al.: A randomized controlled trial to evaluate laparoscopic versus open complete mesocolic excision (CME) for stage II, III colorectal cancer (CRC): First efficacy results from Japan Clinical Oncology Group Study JCOG0404. Gastrointestinal Cancer Symposium. Jan 2015.
      Y Nishizawa, M Ito, N Saito, et al.: Risk factors for postoperative complications of a randmized clinical trial: Laparoscopic versus open surgery with D3 lymphadenectomy for stage II/III colon cancer(JCOG0404). Gastrointestinal Cancer Symposium. Jan 2015.
      K Nakajima, M Inomata, T Akagi, et al.: Quality control by photograph for evaluation of open(OP) and laparoscopic(LAP) colectomy with D3 resection for stage II/III colorectal cancer: Japan Clinical Oncology Group study JCOG 0404. 2014 ASCO Annual Meeting. May 2014.
      長谷川博俊、石井良幸、斉田芳久、他:大腸癌に対する腹腔鏡下 vs 開腹手術のRCTに基づく日本からのエビデンスの発信 - JCOG0404の短期成績 -. 第68回日本消化器外科学会総会. 2013年7月.
      S Yamamoto, M Inomata, S Kitano, et al.: Short-term clinical outcomes from a randomized controlled trial to evaluate laparoscopic and open surgery for stage Ⅱ-Ⅲ colorectal cancer: Japan Clinical Oncology Group study JCOG 0404. 2012 Gastrointestinal Cancers Symposium. Jan 2012.
      Y Nishizawa, M Inomata, et al.: Short-term clinical outcomes from a randomized controlled trial to evaluate laparoscopic versus open complete mesocolic excision for stage Ⅱ,Ⅲ colorectal cancer (CRC): Japan Clinical Oncology Group study JCOG 0404. 48th Annual Meeting of the American Society of Clinical Oncology. Jun 2012.
      絹笠祐介、猪股雅史、北野正剛、他:進行大腸癌に対する腹腔鏡下手術と開腹手術とのランダム化比較試験(JCOG0404);短期成績の報告.第50回日本癌治療学会学術集会.2012年10月.
      JCOG0603
      金光幸秀、加藤知行、清水泰博、他:わが国における消化器癌補助療法に関する臨床試験によるエビデンス-大腸癌術後補助療法に関するJCOG studyの概要.第110回日本外科学会定期学術集会.2010年4月.
      JCOG0910
      Y Yoshida, K Yamazaki, J Mizusawa, et al.: Predictive factor for toxicities and treatment termination in adjuvant capecitabine therapy for stage III colorectal cancer; based on the data of a randomized trial, JCOG0910.ESMO2015 Poster discussion. Sep 2015.
      T Hamaguchi, Y Shimada, J Mizusawa, et al.: Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC): Results of Japan Clinical Oncology Group study (JCOG0910). ASCO2015 Poster discussion. May 2015.
    2. グループ代表者管理の治療研究
      JCOG0903
      高島淳生、濱口哲弥、伊藤芳紀、他:肛門管扁平上皮癌に対する治療の国内における現状調査.第45回日本癌治療学会総会.2007年10月.
    3. 附随研究等
      JCOG0404
      衛藤剛、猪股雅史、北野正剛、他:進行大腸癌に対する腹腔鏡/開腹手術のRCT(JCOG0404):患者説明同意状況.第50回日本癌治療学会学術集会.2012年10月.
      JCOG1007
      金光幸秀、平井孝、小森康司、他:切除不能同時性肝転移大腸癌症例に対する原発巣切除の意義.第68回日本臨床外科学会総会.2006年11月.
      JCOG1018
      濱口哲弥.: 高齢者大腸癌患者に対する臨床試験(JCOG1018試験)を開始してわかりつつあること. 第27回日本サイコオンコロジー学会. 2014年10月.
      小川朝生、長島文夫、濱口哲弥:高齢者総合機能評価法(Cancer Specific Geriatric Assessment).第50回日本癌治療学会学術集会.2012年10月.
      長島 文夫、北村 浩、宮島 謙介、他: Unfit populationに対するがん化学療法の現状とエビデンス構築のための臨床試験 高齢者を対象としたがん化学療法と臨床開発(消化器)切除不能大腸がんを対象とした第3相試験(JCOG1018)と高齢者総合的機能評価. 臨床薬理. 2012.
      小川朝生、長島文夫、濱口哲弥:Cancer Specific Geriatric Assessment (CSGA)日本語版の開発.第77回大腸癌研究会.2012年7月.
    4. 総説・解説
      JCOG0404
      猪股雅史、北野正剛、他:進行大腸癌に対する腹腔鏡下手術の第Ⅲ相試験.第24回日本内視鏡外科学会総会.2011年12月.
      S Yamamoto, M Inomata, et al.: Short-term clinical outcomes from a randomized controlled trial to evaluate laparoscopic and open surgery for stage Ⅱ-Ⅲ colorectal cancer: Japan Clinical Oncology Group study JCOG 0404. The International Surgical Week 2011. Aug 2011.
トップへ戻る